Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.
暂无分享,去创建一个
[1] T. Pawson,et al. The ShcA SH2 domain engages a 14-3-3/PI3′K signaling complex and promotes breast cancer cell survival , 2012, Oncogene.
[2] C. Arteaga,et al. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. , 2011, Cancer research.
[3] Carlos L. Arteaga,et al. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors , 2011, Proceedings of the National Academy of Sciences.
[4] J. McManaman,et al. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. , 2010, Cancer research.
[5] J. Baselga,et al. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.
[6] D. Stern,et al. ErbB3 is required for ductal morphogenesis in the mouse mammary gland , 2008, Breast Cancer Research.
[7] D. Stern. ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.
[8] R. Cardiff,et al. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression , 2007, Proceedings of the National Academy of Sciences.
[9] M. Moasser. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis , 2007, Oncogene.
[10] M. Moasser,et al. Targeting HER proteins in cancer therapy and the role of the non-target HER3 , 2007, British Journal of Cancer.
[11] Robert D. Cardiff,et al. Insights from transgenic mouse models of ERBB2-induced breast cancer , 2007, Nature Reviews Cancer.
[12] W. Muller,et al. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer , 2007, Oncogene.
[13] K. Shokat,et al. Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.
[14] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[15] L. Anderson,et al. Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1. , 2005, American journal of respiratory cell and molecular biology.
[16] H. Lane,et al. ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.
[17] M. Mann,et al. Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.
[18] E. Andrechek,et al. Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth , 2005, Oncogene.
[19] D. Stern,et al. ErbB2 is required for ductal morphogenesis of the mammary gland. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[20] R. Cardiff,et al. Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression , 2003, Oncogene.
[21] F. Maurer,et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[22] A. Citri,et al. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.
[23] D. Stern,et al. ErbBs in mammary development. , 2003, Experimental cell research.
[24] C. Mounier,et al. Epidermal Growth Factor-induced DNA Synthesis , 2003, The Journal of Biological Chemistry.
[25] Brian Higgins,et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.
[26] S. Eccles. The Role of c-erbB-2/HER2/neu in Breast Cancer Progression and Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.
[27] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[28] M. Holzenberger,et al. A targeted partial invalidation of the insulin-like growth factor I receptor gene in mice causes a postnatal growth deficit. , 2000, Endocrinology.
[29] R. Neve,et al. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells , 2000, Oncogene.
[30] K. Darcy,et al. Changes in ErbB2 (her-2/neu), ErbB3, and ErbB4 during Growth, Differentiation, and Apoptosis of Normal Rat Mammary Epithelial Cells , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[31] D. Stern,et al. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation , 1999, Oncogene.
[32] R. Cardiff,et al. Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.
[33] Kuala Lumpur Malaysia,et al. Expression of c-erbB3 protein in primary breast carcinomas. , 1998, British Journal of Cancer.
[34] D. Riethmacher,et al. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor , 1997, Nature.
[35] M. Moran,et al. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation , 1997, Molecular and cellular biology.
[36] J. Luck,et al. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. , 1997, Anticancer research.
[37] Kuo-Fen Lee,et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.
[38] K. Herrup,et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.
[39] N. Hynes,et al. The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.
[40] C. Quinn,et al. c‐erbB‐3 protein expression in human breast cancer: comparison with other tumour variables and survival , 1994, Histopathology.
[41] L. Cantley,et al. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor , 1994, Molecular and cellular biology.
[42] W. Gullick,et al. Identification of c‐erbB‐3 binding sites for phosphatidylinositol 3′‐kinase and SHC using an EGF receptor/c‐erbB‐3 chimera. , 1994, The EMBO journal.
[43] Andrea Richardson,et al. A role for the scaffolding adapter GAB2 in breast cancer , 2006, Nature Medicine.
[44] David C. Lee,et al. Regulation of Mouse Mammary Gland Development and Tumorigenesis by the ERBB Signaling Network , 2004, Journal of Mammary Gland Biology and Neoplasia.
[45] E. Kubista,et al. Comparative analysis of two-dimensional protein patterns in malignant and normal human breast tissue. , 2001, Cancer detection and prevention.